Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
Anesthesia and Analgesia shared an insightful post on LinkedIn:
“When compared to cryoprecipitate, can fibrinogen concentrate adequately restore hemostasis and reduce postoperative thrombosis risk in neonates undergoing cardiac surgery with cardiopulmonary bypass (CPB)?
Patients who received fibrinogen concentrate CPB had similar ex vivo clot degradation rates throughout the immediate perioperative period with greater degradation at 24 hours postoperatively and received less post-CPB blood products with no increased risk of bleeding or thrombotic complications when compared to patients who received cryoprecipitate.
Given the increased risks associated with allogenic blood transfusions, our results suggest that fibrinogen concentrate may be a suitable alternative to achieve perioperative hemostasis in neonates undergoing cardiac surgery without increased risk of thrombotic or bleeding complications.”
Read the full article here.
Article: Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery
Authors: Laura A. Downey, Nina Moiseiwitsch, Kimberly Nellenbach, Yijin Xiang, Ashley C. Brown, Nina A.
Stay updated on the latest scientific advances in the field of clotting disorders with Hemostasis Today.
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 15, 2025, 23:31Richard Buka: Many Improvements Needed in HIT Management
-
Aug 14, 2025, 23:47World Thrombosis Day: Know your Risk in DVT
-
Aug 14, 2025, 12:52JAMA Review: Immune Thrombotic Thrombocytopenic Purpura (iTTP)
-
Aug 14, 2025, 12:33Louise Bannon: The World Thrombosis Day Campaign is Calling on Industry Leaders
-
Aug 15, 2025, 23:35SEC61B Mediated Platelet Hyperactivity in People with Diabetes
-
Aug 15, 2025, 23:32Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
-
Aug 15, 2025, 23:31Marc Carrier: Low Awareness of Cancer-Associated Thrombosis Among Canadians
-
Aug 14, 2025, 23:47Health-related Quality of Life in Children with von Willebrand Disease
-
Aug 14, 2025, 17:54Omid Seidizadeh: From Genotype and Phenotype! Variability in Type 2 von Willebrand Disease
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact